Advertisement

Heart Failure pp 179-189 | Cite as

Psychological Comorbidities in Heart Failure

  • Christiane E. AngermannEmail author
  • Julia Wallenborn
Chapter
Part of the Cardiovascular Medicine book series (CVM)

Abstract

Heart failure limits functional capacity and life expectancy, compromises quality of life and is associated with high healthcare costs. This is due not only to the physical symptoms of cardiac disease, but also to psychological comorbidities such as depression, anxiety and cognitive dysfunction. These comorbidities are much more common in patients with heart disease compared with the general population, and are associated with frequent decompensations and higher risk of hospitalization in heart failure. Demographic, biological, behaviour-related and psychosocial factors modulate the interaction between physical and mental disorders and should be considered in patient treatment. Screening tools can be easily applied to facilitate early detection. Multidisciplinary, individualized therapeutic approaches and physical activity improve patients’ well-being. In addition, active participation of patients in managing their somatic disease seems particularly important. To date, antidepressant pharmacotherapy has not shown any positive effects on mood and prognosis in patients with heart failure.

Keywords

Clinical relevance Recognition and treatment of depression Anxiety and cognitive dysfunction 

References

  1. 1.
    Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48(8):1527–37.PubMedGoogle Scholar
  2. 2.
    Vaccarino V, Kasl SV, Abramson J, Krumholz HM. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol. 2001;38(1):199–205.PubMedGoogle Scholar
  3. 3.
    Konstam V, Moser DK, De Jong MJ. Depression and anxiety in heart failure. J Card Fail. 2005;11(6):455–63.PubMedGoogle Scholar
  4. 4.
    Angermann CE, Gelbrich G, Stork S, Schowalter M, Deckert J, Ertl G, et al. Somatic correlates of comorbid major depression in patients with systolic heart failure. Int J Cardiol. 2011;147(1):66–73.PubMedGoogle Scholar
  5. 5.
    Faller H, Stork S, Schowalter M, Steinbuchel T, Wollner V, Ertl G, et al. Depression and survival in chronic heart failure: does gender play a role? Eur J Heart Fail. 2007;9(10):1018–23.PubMedGoogle Scholar
  6. 6.
    Dekker RL, Lennie TA, Doering LV, Chung ML, Wu JR, Moser DK. Coexisting anxiety and depressive symptoms in patients with heart failure. Eur J Cardiovasc Nurs. 2014;13(2):168–76.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Suzuki T, Shiga T, Kuwahara K, Kobayashi S, Suzuki S, Nishimura K, et al. Impact of clustered depression and anxiety on mortality and rehospitalization in patients with heart failure. J Cardiol. 2014;64(6):456–62.PubMedGoogle Scholar
  8. 8.
    Chapa DW, Akintade B, Son H, Woltz P, Hunt D, Friedmann E, et al. Pathophysiological relationships between heart failure and depression and anxiety. Crit Care Nurse. 2014;34(2):14–24. quiz 5PubMedGoogle Scholar
  9. 9.
    Angermann CE, Kaspar M, Marx A, Kittel-Schneider S, Menhofer D, Stork S, et al. A functional variant of the neuropeptide S receptor-1 gene modulates clinical outcomes and healthcare utilization in patients with systolic heart failure: results from the Interdisciplinary Network Heart Failure (INH) Study. Eur J Heart Fail. 2017;19(3):314–23.PubMedGoogle Scholar
  10. 10.
    Alosco ML, Spitznagel MB, Raz N, Cohen R, Sweet LH, Colbert LH, et al. Obesity interacts with cerebral hypoperfusion to exacerbate cognitive impairment in older adults with heart failure. Cerebrovasc Dis Extra. 2012;2(1):88–98.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Gure TR, Blaum CS, Giordani B, Koelling TM, Galecki A, Pressler SJ, et al. Prevalence of cognitive impairment in older adults with heart failure. J Am Geriatr Soc. 2012;60(9):1724–9.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Almeida OP, Garrido GJ, Beer C, Lautenschlager NT, Arnolda L, Flicker L. Cognitive and brain changes associated with ischaemic heart disease and heart failure. Eur Heart J. 2012;33(14):1769–76.PubMedGoogle Scholar
  13. 13.
    McCaffery JM, Frasure-Smith N, Dube MP, Theroux P, Rouleau GA, Duan Q, et al. Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med. 2006;68(2):187–200.PubMedGoogle Scholar
  14. 14.
    Domschke K, Reif A, Weber H, Richter J, Hohoff C, Ohrmann P, et al. Neuropeptide S receptor gene – converging evidence for a role in panic disorder. Mol Psychiatry. 2011;16(9):938–48.PubMedGoogle Scholar
  15. 15.
    Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. J Am Coll Cardiol. 2005;45(5):637–51.PubMedGoogle Scholar
  16. 16.
    Carney RM, Freedland KE, Veith RC. Depression, the autonomic nervous system, and coronary heart disease. Psychosom Med. 2005;67(Suppl 1):S29–33.PubMedGoogle Scholar
  17. 17.
    Kliks BR, Burgess MJ, Abildskov JA. Influence of sympathetic tone on ventricular fibrillation threshold during experimental coronary occlusion. Am J Cardiol. 1975;36(1):45–9.PubMedGoogle Scholar
  18. 18.
    Schwartz PJ. The autonomic nervous system and sudden death. Eur Heart J. 1998;19(Suppl F):F72–80.PubMedGoogle Scholar
  19. 19.
    Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, et al. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress. Circ Heart Fail. 2009;2(6):608–15.PubMedGoogle Scholar
  20. 20.
    Grippo AJ, Johnson AK. Biological mechanisms in the relationship between depression and heart disease. Neurosci Biobehav Rev. 2002;26(8):941–62.PubMedGoogle Scholar
  21. 21.
    Kop WJ, Gottdiener JS. The role of immune system parameters in the relationship between depression and coronary artery disease. Psychosom Med. 2005;67(Suppl 1):S37–41.PubMedGoogle Scholar
  22. 22.
    Mahmoudi M, Curzen N, Gallagher PJ. Atherogenesis: the role of inflammation and infection. Histopathology. 2007;50(5):535–46.PubMedGoogle Scholar
  23. 23.
    Engelhardt S, Patkar S, Ogunshola OO. Cell-specific blood-brain barrier regulation in health and disease: a focus on hypoxia. Br J Pharmacol. 2014;171(5):1210–30.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Ampadu J, Morley JE. Heart failure and cognitive dysfunction. Int J Cardiol. 2015;178:12–23.PubMedGoogle Scholar
  25. 25.
    Fan H, Yu W, Zhang Q, Cao H, Li J, Wang J, et al. Depression after heart failure and risk of cardiovascular and all-cause mortality: a meta-analysis. Prev Med. 2014;63:36–42.PubMedGoogle Scholar
  26. 26.
    Bane C, Hughes CM, McElnay JC. The impact of depressive symptoms and psychosocial factors on medication adherence in cardiovascular disease. Patient Educ Couns. 2006;60(2):187–93.PubMedGoogle Scholar
  27. 27.
    Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Depression and cardiovascular disease: a clinical review. Eur Heart J. 2014;35(21):1365–72.PubMedGoogle Scholar
  28. 28.
    World Health Organization. ICD-10 Classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.Google Scholar
  29. 29.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5). Arlington: American Psychiatric Publishing; 2013.Google Scholar
  30. 30.
    Lowe B, Grafe K, Zipfel S, Witte S, Loerch B, Herzog W. Diagnosing ICD-10 depressive episodes: superior criterion validity of the Patient health questionnaire. Psychother Psychosom. 2004;73(6):386–90.PubMedGoogle Scholar
  31. 31.
    Spitzer RL, Williams JB, Gibbon M, First MB. The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry. 1992;49(8):624–9.PubMedGoogle Scholar
  32. 32.
    Lowe B, Kroenke K, Grafe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). J Psychosom Res. 2005;58(2):163–71.PubMedGoogle Scholar
  33. 33.
    Piepenburg SM, Faller H, Gelbrich G, Stork S, Warrings B, Ertl G, et al. Comparative potential of the 2-item versus the 9-item patient health questionnaire to predict death or rehospitalization in heart failure. Circ Heart Fail. 2015;8(3):464–72.PubMedGoogle Scholar
  34. 34.
    Lichtman JH, Bigger JT Jr, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesperance F, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association prevention committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research: endorsed by the American Psychiatric Association. Circulation. 2008;118(17):1768–75.PubMedGoogle Scholar
  35. 35.
    Kroenke K, Spitzer RL, Williams JB. The patient health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284–92.PubMedGoogle Scholar
  36. 36.
    Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.PubMedGoogle Scholar
  37. 37.
    Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317–25.PubMedGoogle Scholar
  38. 38.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.PubMedGoogle Scholar
  39. 39.
    Dodson JA, Chaudhry SI. Geriatric conditions in heart failure. Curr Cardiovasc Risk Rep. 2012;6(5):404–10.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Harkness K, Demers C, Heckman GA, McKelvie RS. Screening for cognitive deficits using the Montreal cognitive assessment tool in outpatients >/=65 years of age with heart failure. Am J Cardiol. 2011;107(8):1203–7.PubMedGoogle Scholar
  41. 41.
    Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden LH, Cuffe MS, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161(15):1849–56.PubMedGoogle Scholar
  42. 42.
    Jiang W, Krishnan R, Kuchibhatla M, Cuffe MS, Martsberger C, Arias RM, et al. Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). Am J Cardiol. 2011;107(4):545–51.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Moraska AR, Chamberlain AM, Shah ND, Vickers KS, Rummans TA, Dunlay SM, et al. Depression, healthcare utilization, and death in heart failure: A community study. Circ Heart Fail. 2013;6(3):387.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Sayers SL, Hanrahan N, Kutney A, Clarke SP, Reis BF, Riegel B. Psychiatric comorbidity and greater hospitalization risk, longer length of stay, and higher hospitalization costs in older adults with heart failure. J Am Geriatr Soc. 2007;55(10):1585–91.PubMedGoogle Scholar
  45. 45.
    Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med. 2003;65(2):201–10.PubMedGoogle Scholar
  46. 46.
    De Jong MJ, Chung ML, Wu JR, Riegel B, Rayens MK, Moser DK. Linkages between anxiety and outcomes in heart failure. Heart Lung. 2011;40(5):393–404.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.PubMedGoogle Scholar
  48. 48.
    Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108(1):2–8.PubMedGoogle Scholar
  49. 49.
    Piepenburg SM, Ertl G, Angermann CE. Depression und Herzinsuffizienz – eine gefährliche Kombination. Dtsch Med Wochenschr. 2016;141(17):1222–7. (im Druck)PubMedGoogle Scholar
  50. 50.
    Wallenborn J, Angermann CE. Comorbid depression in heart failure. Herz. 2013;38(6):587–96.PubMedGoogle Scholar
  51. 51.
    Woltz PC, Chapa DW, Friedmann E, Son H, Akintade B, Thomas SA. Effects of interventions on depression in heart failure: a systematic review. Heart Lung. 2012;41(5):469–83.PubMedGoogle Scholar
  52. 52.
    Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701–9.PubMedGoogle Scholar
  53. 53.
    Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA. 2003;289(23):3106–16.PubMedGoogle Scholar
  54. 54.
    Lesperance F, Frasure-Smith N, Koszycki D, Laliberte MA, van Zyl LT, Baker B, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297(4):367–79.PubMedGoogle Scholar
  55. 55.
    van den Brink RH, van Melle JP, Honig A, Schene AH, Crijns HJ, Lambert FP, et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). Am Heart J. 2002;144(2):219–25.PubMedGoogle Scholar
  56. 56.
    O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56(9):692–9.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Angermann CE, Gelbrich G, Stork S, Gunold H, Edelmann F, Wachter R, et al. Effect of Escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: The MOOD-HF randomized clinical trial. JAMA. 2016;315(24):2683–93.PubMedGoogle Scholar
  58. 58.
    Freedland KE, Carney RM, Rich MW, Steinmeyer BC, Rubin EH. Cognitive behavior therapy for depression and self-care in heart failure patients: a randomized clinical trial. JAMA Intern Med. 2015;175(11):1773–82.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Huffman JC, Mastromauro CA, Beach SR, Celano CM, Dubois CM, Healy BC, et al. Collaborative care for depression and anxiety disorders in patients with recent cardiac events: the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized clinical trial. JAMA Intern Med. 2014;174(6):927–35.PubMedGoogle Scholar
  60. 60.
    Blumenthal JA, Babyak MA, O’Connor C, Keteyian S, Landzberg J, Howlett J, et al. Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. JAMA. 2012;308(5):465–74.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Tu RH, Zeng ZY, Zhong GQ, Wu WF, Lu YJ, Bo ZD, et al. Effects of exercise training on depression in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. Eur J Heart Fail. 2014;16(7):749–57.PubMedGoogle Scholar
  62. 62.
    Jiang W, Oken H, Fiuzat M, Shaw LK, Martsberger C, Kuchibhatla M, et al. Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive disorder. J Cardiovasc Transl Res. 2012;5(1):92–9.PubMedGoogle Scholar
  63. 63.
    Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr. 2010;91(3):757–70.PubMedGoogle Scholar
  64. 64.
    Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223–30.PubMedGoogle Scholar
  65. 65.
    Hedayati SS, Gregg LP, Carmody T, Jain N, Toups M, Rush AJ, et al. Effect of sertraline on depressive symptoms in patients with chronic kidney disease without dialysis dependence: the CAST randomized clinical trial. JAMA. 2017;318(19):1876–90.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Walther CP, Shah AA, Winkelmayer WC. Treating depression in patients with advanced CKD: beyond the generalizability frontier. JAMA. 2017;318(19):1873–4.PubMedGoogle Scholar
  67. 67.
    Gary RA, Dunbar SB, Higgins MK, Musselman DL, Smith AL. Combined exercise and cognitive behavioral therapy improves outcomes in patients with heart failure. J Psychosom Res. 2010;69(2):119–31.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Groot C, Hooghiemstra AM, Raijmakers PG, van Berckel BN, Scheltens P, Scherder EJ, et al. The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Res Rev. 2016;25:13–23.PubMedGoogle Scholar
  69. 69.
    Smith PJ, Blumenthal JA, Hoffman BM, Cooper H, Strauman TA, Welsh-Bohmer K, et al. Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosom Med. 2010;72(3):239–52.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Zheng G, Xia R, Zhou W, Tao J, Chen L. Aerobic exercise ameliorates cognitive function in older adults with mild cognitive impairment: a systematic review and meta-analysis of randomised controlled trials. Br J Sports Med. 2016;50(23):1443–50.PubMedGoogle Scholar
  71. 71.
    Wenger NK. Current status of cardiac rehabilitation. J Am Coll Cardiol. 2008;51(17):1619–31.PubMedGoogle Scholar
  72. 72.
    Perez-Lopez FR, Martinez-Dominguez SJ, Lajusticia H, Chedraui P. Health outcomes systematic analyses P. Effects of programmed exercise on depressive symptoms in midlife and older women: A meta-analysis of randomized controlled trials. Maturitas. 2017;106:38–47.PubMedGoogle Scholar
  73. 73.
    Angermann CE, Stork S, Gelbrich G, Faller H, Jahns R, Frantz S, et al. Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the Interdisciplinary Network for Heart Failure (INH) study. Circ Heart Fail. 2012;5(1):25–35.PubMedGoogle Scholar
  74. 74.
    Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med. 2008;168(3):316–24.PubMedGoogle Scholar
  75. 75.
    Gunold H, Angermann CE. Kognitive Dysfunktion, Depression und Angst bei Herzinsuffizienz. Aktuel Kardol. 2015;4:379–86.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine I and Comprehensive Heart Failure CenterUniversity and University Hospital of WürzburgWürzburgGermany

Personalised recommendations